RE: The Question is:Why $30.....down to 5 cents: Promising treatment for Alzheimer...Alzhemed with promising millions patients in the world...Two major phase 3 trials...2 failures.
Now Kiactatm...50,000 patients in the world...phase 3 begins...GLTA
Vivimind: Forget About It « Science-Based Pharmacy
Vivimind was once a promising prescription drug. It was calledAlzhemed, and was hoped to be a breakthrough treatment for Alzheimer’sdisease. [3]Alzheimer’s disease is a neurodegenerative process, where amyloidplaques form in the brain, leading to dementia. It was proposed thatAlzhemed might reduce the deposits of plaque, slowing progression of thedisease.
A preliminary study examined Alzhemed in mild-to-moderate Alzheimer’sdisease. [4]Researchers studied its safety, tolerability, and pharmacokinetics (howthe drug behaves in the body), but not whether the drug worked.Overall, the study found that Alzhemed was generally well tolerated andappeared safe. There was evidence to show that it did reach the brain.This was encouraging enough to support further studies to answer thequestion: Does the drug actually work?
Two major phase 3 trials were subsequently launched to test ifAlzhemed could be an effective treatment for Alzheimer’s disease.Unfortunately, the results showed that patients taking Alzhemed did nobetter than patients taking a placebo. [3]The FDA concluded that the results could not support a claim ofclinical efficacy – that is, the manufacturer could not claim the drugworked.[5]A European trial of Alzhemed was subsequently discontinued before theresults were reported.
Case closed for Alzhemed? Not quite. After the failure of the phase 3trial, where Alzhemed was shown to be ineffective, the manufacturerannounced its intention to bring the product to market – but not as atreatment for Alzheimer’s. Nope – they were going after a bigger market– people with age associated memory impairment. And forget about allthat pesky evidence and data the FDA wanted. Since approval of Alzhemedas a prescription drug to treat Alzheimer’s disease seemed out of thequestion, the manufacturer, Neurochem, decided to market it as a naturalhealth product. [3][6]The company changed its name to Bellus Health, and renamed the productVivimind.
With respect to AAMI, the currently marketed use for Vivimind, thereare no published trials to demonstrate any positive effects. In fact, thereare no published trials at all that have examined Vivimind forAAMI. Recall that AAMI is considered a natural consequence of ageing.There is currently no medical reason to treat AAMI with any drug, andthere are no demonstrated biological changes of AAMI that could beimpacted by Vivimind.
So the science tells us that Vivimind is a failed prescriptiontreatment for Alzheimer’s disease, and there is no science to supportits current claims for treating AAMI.